Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.70 |
| ▸ | TSHR | P16473 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | MMP9 | P14780 | 1/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.70 |
| ▸ | CA1 | P00915 | 16/20 | 0.36 |
| ▸ | CA2 | P00918 | 16/20 | 0.36 |
| ▸ | CA9 | Q16790 | 14/20 | 0.36 |
| ▸ | CA12 | O43570 | 5/20 | 0.35 |
| ▸ | CA7 | P43166 | 5/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.35 |
| ▸ | CA3 | P07451 | 4/20 | 0.35 |
| ▸ | CA4 | P22748 | 4/20 | 0.35 |
| ▸ | CA6 | P23280 | 4/20 | 0.35 |
| ▸ | CA5A | P35218 | 4/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL921986 | 0.95 | TSHR (0.79) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL6622075 | 0.93 | USP2 (0.61) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL920792 | 0.92 | TSHR (0.75) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL922498 | 0.92 | TSHR (0.75) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL1109868 | 0.92 | TSHR (0.75) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL576408 | 0.89 | TSHR (0.88) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL10068323 | 0.86 | TSHR (0.52) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL263556 | 0.83 | — | — | |
| Busulfan SCHEMBL4373 | 0.83 | TSHR (1.00) | USP2TSHRALDH1A1KDM4ELMNA | |
| Busulfan SCHEMBL4764696 | 0.83 | TSHR (1.00) | USP2TSHRALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011148392-A1 | PROCESS FOR THE PREPARATION OF (2S,4S,5S,7S)-N-(2-CARBAMYL-2- METHYLPROPYL)-5-AMINO-4-HYDROXY-2,7-DIISOPROPYL-8-[4-METHOXY-3-(3- METHOXYPROPOXY)PHENYL]-OCTANAMIDE HEMIFUMARATE AND ITS INTERMEDIATES THEREOF | MSN LABORATORIES LIMITED (IN) | 2011-12-01 | — | — | WO | claimed |
| WO-2007117482-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | claimed |
| CN-114539133-B | Method for preparing prucalopride intermediate 1- (3-methoxypropyl) -4-piperidinamine | 鲁南制药集团股份有限公司 | 2024-09-20 | — | — | CN | disclosed |
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230025807-A1 | CD38 INHIBITORS | Astellas Engineered Small Molecules US, Incorporated | 2023-01-26 | — | — | US | disclosed |
| CN-115197123-A | Preparation method of prucalopride intermediate 1- (3-methoxypropyl) -4-piperidinamine | 山东新时代药业有限公司 | 2022-10-18 | — | — | CN | disclosed |
| US-11446261-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2022-09-20 | — | — | US | disclosed |
| CN-115043773-A | Synthesis method of 4-N-tert-butyloxycarbonyl-1- (3-methoxypropyl) -4-piperidinamine | 山东新时代药业有限公司 | 2022-09-13 | — | — | CN | disclosed |
| CN-114591220-A | Preparation method of prucalopride intermediate 1- (3-methoxypropyl) -4-piperidinamine | 鲁南制药集团股份有限公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-114539134-A | Synthetic method of prucalopride intermediate 1- (3-methoxypropyl) -4-piperidinamine | 鲁南制药集团股份有限公司 | 2022-05-27 | — | — | CN | disclosed |
| US-6969714-B2 | Imidazolo-5-YL-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation | ASTRAZENECA AB (SE) | 2005-11-29 | — | — | US | disclosed |
| US-6969712-B2 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-29 | — | — | US | disclosed |
| US-20050131000-A1 | Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidine with cdk inhibitory activity | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | disclosed |
| EP-1351958-B1 | IMIDAZOLO-5-YL-2-ANILINO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF THE CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2004-06-16 | — | — | EP | disclosed |
| US-20040044056-A1 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-04 | — | — | US | disclosed |
| US-20040014776-A1 | Imidazolo-5-YL-2anilino-pyrimidines as agents for the inhibition of the cell proliffration | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | US | disclosed |
| EP-1342717-A1 | BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-09-10 | — | — | EP | disclosed |
| CN-1377349-A | Quinuclidine compound and medicine containing the same as active ingredient | EISAI CO LTD (JP) | 2002-10-30 | — | — | CN | disclosed |
| US-6187780-B1 | ANTIDEPRESSANTS, ANTIASTHMATIC AGENTS; MIGRAINE | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | USP2 3553/4885TSHR 2964/4885ALDH1A1 140/4885 |
| US-20230025807-A1 | CD38 INHIBITORS | CD38, GLS, IDH2 | USP2 4492/4885TSHR 2701/4885ALDH1A1 140/4885 |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | USP2 3473/4885TSHR 2971/4885ALDH1A1 133/4885 |
| US-20050131000-A1 | Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidine with cdk inhibitory activity | CCNI, CDK2, CDK1 | USP2 2650/4885TSHR 3691/4885ALDH1A1 1079/4885 |
| US-20040014776-A1 | Imidazolo-5-YL-2anilino-pyrimidines as agents for the inhibition of the cell proliffration | CCNI, TYMP, MKI67 | USP2 2437/4885TSHR 2543/4885ALDH1A1 545/4885 |
| US-11446261-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | USP2 3553/4885TSHR 2964/4885ALDH1A1 140/4885 |
| US-20040044056-A1 | Benzimidazole derivatives | GPR119, OPRL1, INSR | USP2 4219/4885TSHR 239/4885ALDH1A1 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.